Antibody offers new hope against ovarian cancer

April 12, 2010

Austrian researchers have found an antibody that could be used to step up the fight against ovarian cancer -- a major killer for women.

The AD5-10 antibody helps to weaken the resistance of in the body's immune system, according to the University of Vienna researchers whose work was published Monday.

The antibody reduced the resistance of tumour cells to a natural resistance mechanism known as Tumour Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL). The TRAIL protein induces to commit suicide.

Some of the tumour cells fail to react to the suicide signal however, making ovarian cancer the most fatal form of disease affecting the female sexual and reproductive organs. The American Cancer Society estimates that about 21,550 new cases of ovarian cancer were diagnosed in the United States in 2009.

The Austrian team's work offers new hope of improved treatment.

"We were able to show in both cell cultures and animal models that TRAIL resistant tumour cells become sensitive to TRAIL again if TRAIL and AD5-10 are both present at the same time", said Michael Krainer, who led study at the university's Faculty of Medicine.

The AD5-10 antibody attaches itself to a different part of the cancer cell than the TRAIL protein, which could explain it's effect, said the Austrian team.

In other tests, they found AD5-10 made several drugs used in chemotherapy more effective.

"We were able to show in cell cultures that the combined effect of AD5-10 and carboplatin (a common chemotherapy agent) was greater than the sum of their effects when administered individually," said Krainer.

"Moreover, tests on animal models showed that AD5-10 can eliminate resistance to carboplatin."

The antibody only reacted in this way when lymphocytes NK -- so-called 'cell killers' -- were present in the tumour at the same time, the researchers said.

Related Stories

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.